Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Lymphoid 2Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × utomilumab × Head & Neck × Clear all
NCT03258008 2022-12-16

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡